Skip to Primary Navigation

Skip to main content

DOJ, DEA reclassify marijuana products as Schedule III drugs

A photo of a gold-colored marijuana leaf hanging outside of shop.
Photo: Smith Collection/Gado/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The changes move products containing marijuana to a less restrictive category, taking significant strides toward the legalization of the drug itself.

Significant steps toward changing how the federal government regulates FDA-approved marijuana products have been announced by the US Department of Justice (DOJ) and the Drug Enforcement Administration (DEA).

According to an April 23 order from the DOJ, FDA-approved drugs that contain marijuana, as well as medical marijuana products regulated by state

, , , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience